Business Standard

Nestle adds skincare muscle by completing Valeant deal

AFP  |  Geneva 

Swiss food giant Nestle announced today that it had bolstered its hand in the medical skin treatment market by finalising a deal with Canada's Valeant Pharmaceuticals International.

"As a result of the successful conclusion of the regulatory process and customary closing conditions, Nestle today completed its of Valeant Pharmaceuticals International's commercialisation rights to several key injectable aesthetic dermatology products in the US and Canada," a statement said.



The deal, worth around USD 1.4 billion, was announced on May 28 but needed a green light from regulators to be complete.

North America accounts for more than half of the fast-growing global medical aesthetics market, according to Nestle.

Among the specialised products to which the rights have been acquired are the corrective facial aesthetic treatments Restylane, Perlane and Emervel.

They are manufactured by Nestle's Galderma medical unit, which sells them in all markets except North America, where Valeant has held the distribution rights.

The deal also covered Dysport, an aesthetic dermatology treatment branded as Azzalure in Europe.

It is sold at the global level by Galderma, which has gained Valeant's rights in North America as well.

Finally, Nestle also acquired global rights to Sculptra, an aesthetic and medical treatment owned by Valeant.

Nestle had made its market intentions clear in February when it announced the creation of its Nestle Skin Health division, following a decision to reduce its stake in French group L'Oreal.

Nestle Skin Health -- which also focuses on hair- and nail-care -- was formally created on June 30.

Its bedrock was Galderma, a Nestle and L'Oreal joint venture which became fully-owned by Nestle on Tuesday after the Swiss group completed its of L'Oreal's 50 per cent stake.

RECOMMENDED FOR YOU

Nestle adds skincare muscle by completing Valeant deal

Swiss food giant Nestle announced today that it had bolstered its hand in the medical skin treatment market by finalising a deal with Canada's Valeant Pharmaceuticals International. "As a result of the successful conclusion of the regulatory process and customary closing conditions, Nestle today completed its acquisition of Valeant Pharmaceuticals International's commercialisation rights to several key injectable aesthetic dermatology products in the US and Canada," a statement said. The deal, worth around USD 1.4 billion, was announced on May 28 but needed a green light from regulators to be complete. North America accounts for more than half of the fast-growing global medical aesthetics market, according to Nestle. Among the specialised products to which the rights have been acquired are the corrective facial aesthetic treatments Restylane, Perlane and Emervel. They are manufactured by Nestle's Galderma medical unit, which sells them in all markets except North America, where ... Swiss food giant Nestle announced today that it had bolstered its hand in the medical skin treatment market by finalising a deal with Canada's Valeant Pharmaceuticals International.

"As a result of the successful conclusion of the regulatory process and customary closing conditions, Nestle today completed its of Valeant Pharmaceuticals International's commercialisation rights to several key injectable aesthetic dermatology products in the US and Canada," a statement said.

The deal, worth around USD 1.4 billion, was announced on May 28 but needed a green light from regulators to be complete.

North America accounts for more than half of the fast-growing global medical aesthetics market, according to Nestle.

Among the specialised products to which the rights have been acquired are the corrective facial aesthetic treatments Restylane, Perlane and Emervel.

They are manufactured by Nestle's Galderma medical unit, which sells them in all markets except North America, where Valeant has held the distribution rights.

The deal also covered Dysport, an aesthetic dermatology treatment branded as Azzalure in Europe.

It is sold at the global level by Galderma, which has gained Valeant's rights in North America as well.

Finally, Nestle also acquired global rights to Sculptra, an aesthetic and medical treatment owned by Valeant.

Nestle had made its market intentions clear in February when it announced the creation of its Nestle Skin Health division, following a decision to reduce its stake in French group L'Oreal.

Nestle Skin Health -- which also focuses on hair- and nail-care -- was formally created on June 30.

Its bedrock was Galderma, a Nestle and L'Oreal joint venture which became fully-owned by Nestle on Tuesday after the Swiss group completed its of L'Oreal's 50 per cent stake.
image
Business Standard
177 22

Nestle adds skincare muscle by completing Valeant deal

Swiss food giant Nestle announced today that it had bolstered its hand in the medical skin treatment market by finalising a deal with Canada's Valeant Pharmaceuticals International.

"As a result of the successful conclusion of the regulatory process and customary closing conditions, Nestle today completed its of Valeant Pharmaceuticals International's commercialisation rights to several key injectable aesthetic dermatology products in the US and Canada," a statement said.

The deal, worth around USD 1.4 billion, was announced on May 28 but needed a green light from regulators to be complete.

North America accounts for more than half of the fast-growing global medical aesthetics market, according to Nestle.

Among the specialised products to which the rights have been acquired are the corrective facial aesthetic treatments Restylane, Perlane and Emervel.

They are manufactured by Nestle's Galderma medical unit, which sells them in all markets except North America, where Valeant has held the distribution rights.

The deal also covered Dysport, an aesthetic dermatology treatment branded as Azzalure in Europe.

It is sold at the global level by Galderma, which has gained Valeant's rights in North America as well.

Finally, Nestle also acquired global rights to Sculptra, an aesthetic and medical treatment owned by Valeant.

Nestle had made its market intentions clear in February when it announced the creation of its Nestle Skin Health division, following a decision to reduce its stake in French group L'Oreal.

Nestle Skin Health -- which also focuses on hair- and nail-care -- was formally created on June 30.

Its bedrock was Galderma, a Nestle and L'Oreal joint venture which became fully-owned by Nestle on Tuesday after the Swiss group completed its of L'Oreal's 50 per cent stake.

image
Business Standard
177 22

Upgrade To Premium Services

Welcome User

Business Standard is happy to inform you of the launch of "Business Standard Premium Services"

As a premium subscriber you get an across device unfettered access to a range of services which include:

  • Access Exclusive content - articles, features & opinion pieces
  • Weekly Industry/Genre specific newsletters - Choose multiple industries/genres
  • Access to 17 plus years of content archives
  • Set Stock price alerts for your portfolio and watch list and get them delivered to your e-mail box
  • End of day news alerts on 5 companies (via email)
  • NEW: Get seamless access to WSJ.com at a great price. No additional sign-up required.
 

Premium Services

In Partnership with

 

Dear Guest,

 

Welcome to the premium services of Business Standard brought to you courtesy FIS.
Kindly visit the Manage my subscription page to discover the benefits of this programme.

Enjoy Reading!
Team Business Standard